Form 4: TriSalus Life Sciences Director Acquires Shares in Recent Transaction
SEC Form 4 Filing
Director Mats Wahlstrom acquired 25,188 shares of TriSalus Life Sciences common stock at $3.97 per share on December 17, 2024.
Summary
- Mats Wahlstrom, a director of TriSalus Life Sciences, acquired 25,188 shares of common stock on December 17, 2024, at a price of $3.97 per share.
- This transaction was part of a Securities Purchase Agreement finalized on December 12, 2024.
- Following the transaction, Wahlstrom directly owns 40,915 shares.
- Wahlstrom also has indirect ownership of 1,254,259 shares through Leonard Capital LLC and 1,370,028 shares through HW Investment Partners, LLC.
- Wahlstrom shares voting and investment discretion with his spouse regarding the shares held by Leonard Capital LLC and is a managing member of HW Investment Partners, LLC, sharing voting and investment discretion for those shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director's purchase of shares could be seen as a positive sign, but it's a routine transaction and doesn't provide strong evidence of a significant shift in the company's outlook.
Positives
- The director's purchase of shares could be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders who trade shares in their own company. It provides transparency into the transactions of company directors and officers.
Comparison to Industry Standards
- SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
- The transaction is typical for directors and officers who are acquiring or disposing of shares in their company.
- The filing is consistent with regulatory requirements for insider trading transparency.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder confidence due to the director's purchase.
Key Dates
| Date | Description |
|---|---|
| 12/12/2024 | Date of the Securities Purchase Agreement between the Issuer and Reporting Person. |
| 12/17/2024 | Date of the share acquisition by Mats Wahlstrom. |
| 12/19/2024 | Date of the filing of the SEC Form 4. |
Keywords
TriSalus Life Sciences, Mats Wahlstrom, share acquisition, director, common stock, insider trading, securities purchase agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.